Benzimidazole derivatives: preparation and pharmaceutical applications

A method of treating hematologic malignancies in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of formula:

• wherein
• R1 is selected from the group consisting of:
• C1-C10 alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, C4-C9 heterocycloalkylalkyl, each of which may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of:
• alkylamino, acylamino, and aminoalkyl;
• R2 is selected from the group consisting of:
• H, halogen, and unsubstituted or substituted C1-C10 alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, cycloalkylalkyl, C4-C9 heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each of which may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of:
• halogen, ═O, ═S, —CN, —NO2, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, phenoxy, benzyloxy, alkylamino, acylamino, aminoalkyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, —COOH, —C(O)OR5, —SH, and acyl;
• R3 is selected from the group consisting of H, C1-C6 alkyl, and acyl;
• X and Y are each independently selected from the group consisting of:
• H, halogen, —CN, —NO2, —CF3, C1-C4 alkyl, —COR5, —SR6, —OR6, and —NR7R8;
• R5 is C1-C4 alkyl;
• R6 is C1-C4 alkyl;
• R7 and R8 are each independently selected from the group consisting of:
• H, C1-C4 alkyl, C4-C9 cycloalkyl, C4-C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
• or a pharmaceutically acceptable salt thereof.